{
    "pmcid": "11793827",
    "qa_pairs": {
        "How did the machine learning model contribute to the identification of effective HCAbs against Omicron variants?": [
            "It predicted HCAb efficacy, reducing experimental screening efforts",
            "It directly synthesized new HCAbs with enhanced binding",
            "It replaced the need for ELISA-based assays",
            "It identified new mutations in the spike protein"
        ],
        "What advantage do nanobodies (Nbs) have over traditional antibodies in the context of SARS-CoV-2?": [
            "Their small size, high stability, and ability to bind to unique epitopes",
            "Their ability to induce a stronger immune response",
            "Their longer half-life in the bloodstream",
            "Their higher production yield in mammalian cells"
        ],
        "What is the primary target for neutralizing antibodies in the SARS-CoV-2 spike protein?": [
            "The receptor-binding domain (RBD)",
            "The N-terminal domain (NTD)",
            "The S2 subunit",
            "The fusion peptide"
        ],
        "What potential application is suggested for HCAbs that show cross-variant binding?": [
            "Use in antibody cocktails or as bispecific antibodies",
            "Development as a standalone vaccine",
            "Use in diagnostic testing for SARS-CoV-2",
            "Application in gene therapy for COVID-19"
        ],
        "Which mutations in the SARS-CoV-2 spike protein are highlighted for increasing transmissibility and immune escape?": [
            "E484K, N501Y, L452R, and T478K",
            "D614G, P681R, Q677H, and A222V",
            "K417N, Y453F, S477N, and F490S",
            "H69/V70 deletion, N439K, G446V, and S494P"
        ]
    }
}